United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,814,815.44. The trade was a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.

United Therapeutics Price Performance

UTHR stock opened at $570.75 on Thursday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a market capitalization of $24.23 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 1.87 and a beta of 0.60. The business has a 50 day simple moving average of $565.54 and a two-hundred day simple moving average of $514.75.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on UTHR shares. HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Royal Bank Of Canada decreased their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC grew its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares in the last quarter. Bull Harbor Capital LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth $494,000. Strategic Investment Advisors MI lifted its stake in shares of United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after purchasing an additional 1,662 shares during the last quarter. Talon Private Wealth LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth approximately $3,038,000. Finally, Royal Bank of Canada boosted its holdings in shares of United Therapeutics by 3.3% in the 1st quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock worth $35,075,000 after purchasing an additional 1,864 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.